Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2001-11-02
2004-04-27
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S568000, C514S057000
Reexamination Certificate
active
06727286
ABSTRACT:
The present invention relates to a pharmaceutical composition for oral or injectable (parenteral) use containing 2-(4-isobutylphenyl) propionic acid and a basic amino acid, and more particularly, where the amino acid is arginine.
BACKGROUND OF INVENTION
2-(4-isobutylphenyl) propionic acid, whose International Nonproprietary Name is ibuprofen, is a well-known anti-inflammatory drug having a molecular weight of 206.28 and the following chemical structure:
(Merck Index 12th ed., n4925, page 839). Originally patented in the 1960's, ibuprofen is now marketed generically, as well as under the tradenames of Motrin®, Advil®, and Nuprin® for the treatment of pain, inflammation, and fever.
Ibuprofen is readily available as the racemic mixture ((RS)-Ibuprofen) of the two enantiomers, (R)-Ibuprofen and (S)-Ibuprofen. Even though the (S) enantiomer is the biologically active form, most preparations contain the racemic mixture since the (R) enantiomer is converted to the active (S) form in-vivo. For simplicity, hereinafter the term “ibuprofen” will be used to indicate any one of the (R) enantiomer, the (S) enantiomer, or the racemate.
Many amino acids, including arginine, are available as both the D and L forms. For simplicity, hereinafter the term “arginine” will indicate the D or L form of arginine or a mixture of (D)-arginine and (L)-arginine. Arginine has a molecular weight of 174.20.
Although ibuprofen has many advantages over other analgesics such as aspirin and acetaminophen, it is very poorly soluble in water. Thus, certain dosage forms of ibuprofen, especially oral or injectable liquids, have been difficult to develop. Several U.S. patents have addressed this problem.
For example, U.S. Pat. No. 4,309,421 appears to describe water-soluble complexes of ibuprofen and phospholipids suitable for parenteral administration. U.S. Pat. Nos. 4,859,704 and 4,861,797 appear to describe the synthesis of alkali metal salts of ibuprofen for preparing a liquid ibuprofen formulation.
Other U.S. patents appear to address this problem by preparing an ibuprofen salt with a basic amino acid as the active pharmaceutical ingredient and then solubilizing the salt to produce a liquid dosage form.
For example, U.S. Pat. No. 5,200,558 appears to describe enhanced analgesic effects of S (+) ibuprofen as salts of L and D amino acids, including arginine, in various dosage forms, including as an injectable solution. U.S. Pat. No. 4,279,926 appears to describe the use of basic amino acid salts of propionic acids for relieving pain and treating inflammatory conditions. Similarly, U.S. Pat. No. 5,463,117 appears to describe the preparation of salts of ibuprofen with basic amino acids. Finally, U.S. Pat. No. 6,005,005 appears to describe a liquid composition for oral use containing ibuprofen and arginine.
However, the approaches described in the patents discussed above have, among others, the disadvantage of requiring the formation of a salt before solubilization, where the salt must be isolated and tested prior to producing the dosage form. Additionally, the ibuprofen formulations resulting from those processes have at least a 1:1 molar ratio of amino acid to ibuprofen. It is beneficial from both a cost and development point to not have to form a salt and isolate and test it prior to producing the dosage form. It is also beneficial in most cases to minimize the amount of non-active components, including salts, used in therapeutic products in order to minimize potential side effects. Furthermore, for injectable products it is beneficial to produce a liquid dosage form of ibuprofen having a pH similar to that of blood (pH 7.4). Finally, it is beneficial for an injectable and oral product to have similar pharmacokinetics to minimize the need for dosage adjustments.
SUMMARY OF THE INVENTION
The present invention utilizes arginine to solubilize ibuprofen during the manufacture of the pharmaceutical product instead of using a salt form of ibuprofen. Thus, an embodiment of the present invention is a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1. Another embodiment of the present invention is a method of making a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1. Still other embodiments of the present invention are directed to methods of treating pain, inflammation, fever, and/or other conditions alleviated by ibuprofen comprising administering a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1.
REFERENCES:
patent: 4279926 (1981-07-01), Bruzzese et al.
patent: 4593044 (1986-06-01), Metz
patent: 4687781 (1987-08-01), Ehrenpreis et al.
patent: 4748174 (1988-05-01), Veronesi
patent: 4834966 (1989-05-01), Gazzaniga et al.
patent: 5019563 (1991-05-01), Hunter et al.
patent: 5028625 (1991-07-01), Motola et al.
patent: 5200558 (1993-04-01), Kwan
patent: 5324749 (1994-06-01), Woog et al.
patent: 5463117 (1995-10-01), Stroppolo et al.
patent: 5500226 (1996-03-01), Stroppolo et al.
patent: 5510385 (1996-04-01), Stroppolo et al.
patent: 5519057 (1996-05-01), Loew et al.
patent: 5645857 (1997-07-01), Stroppolo et al.
patent: 5693312 (1997-12-01), Stroppolo et al.
patent: 6005005 (1999-12-01), Stroppolo et al.
patent: 63093718 (1988-04-01), None
patent: 91/15202 (1991-10-01), None
Carter et al, Chemotherapy of Cancer, 1981, Appendix C pp. 361-367.*
Van Overmeire, B., et al., “A Comparison of Ibuprofen and Indomethacin for Closure of Patent Ductus Arteriosus,”The New England Journal of Medicine343:674-681 (2000).
Dormond, O., et al., “Inhibition of Tumor Angiogenesis by Non-Steroidal Anti-Inflammatory Drugs: Emerging Mechanisms and Therapeutic Perspectives,”Drug Resistance Updates, 4:314-321 (2001).
Elmore, E., et al., “Comparative Tissue-Specific Toxicities of 20 Cancer Preventive Agents Using Cultured Cells From 8 Different Normal Human Epithelia,”In Vitro&Molecular Toxicology14:191-207 (2001).
Wargovich, M.J., et al., “Inhibition of Aberrant Crypt Growth by Non-Steroidal Anti-Inflammatory Agenty and Differentiation Agents in the Rat Colon,”Int. J. Cancer, 60:515-519 (1995).
Asea, A., et al., “Cyclooxygenase Inhibitors are Potent Sensitizers of Prostate Tumors to Hyperthermia and Radiation,”Int. J. Hyperthermia, 17:401-414 (2001).
Eberlein, T.J., et al., “Ibuprofen Causes Reduced Toxic Effects of Interleukin 2 Administration in Patients with Metastatic Cancer,”Arch. Surg., 124:542-547 (1989).
Uotila, P., et al., “Increased Expression of Cyclooxygenase-2 and Nitric Oxide Synthase-2 in Human Prostate Cancer,”Urol. Res., 29:25-28 (2001).
Dang, C.T., et al., “Potential Role of Selective COX-2 Inhibitors in Cancer Management,”Oncology, 16:30-36 (2002).
Maitra, A., et al., “Cyclooxygenase 2 Expression in Pancreatic Adenocarcinoma and pancreatic Intraepithelial Neoplasia,”Anatomic Pathology, 118:194-201 (2002).
An, K.P., et al., “Cyclooxygenase-2 Express in Murine and Human Nonmelanoma Skin Cancers: Implications for Therapeutic Approaches,”Photochemistry and Photobiology, 76:73-80 (2002).
McEntee, M.F., et al. “Cyclooxygenase-2 Expression in Spontaneous Intestinal Neoplasia of Domestic Dogs,”Vet. Pathol., 29:428-436 (2002).
Lin, SK., et al., “Sequential Expressions of MMP-1, TIMP-1, IL-6, and COX-2 Genes in Induced Periapical Lesions in Rats,”Eur. J. Oral. Sci., 110:246-253 (2002).
Koki, A.T., et al., “Characterization of Cyclooxygenase-2 (COX-2) during Tumorigenesis in Human Epithelial Cancers: Evidence for Potential Clinical Utility of COX-2 Inhibitors in Epithelial Cancers,”Prostaglandins, Leukotrienes and Essential Fatty Acids, 66:13-18 (2002).
Kawamoto, T., et al., “Expression of Cyclooxygenase-2 in the Subserosal Layer Correlates with Postsurgical Prognosis of Pathological Tumor Stage 2 Carcinoma of the Gallbladder,”Int. J. Cancer, 98:427-434 (2002).
Jaeckel, E.C., et al., “Correlation of Expression of Cyclooxygenase-2,
Cook Rebecca
Cumberland Pharmaceuticals Inc.
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
LandOfFree
Pharmaceutical composition of 2-(4-isobutylphenyl) propionic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition of 2-(4-isobutylphenyl) propionic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition of 2-(4-isobutylphenyl) propionic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3256513